Study Summary
This study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells. Primary Objective: To determine the safety profile and propose the recommended phase 2 dose (RP2D) of autologous CD19-CD22-CAR T cells in patients ≤ 21 years of age with recurrent/refractory CD19- and/or CD22-positive leukemia. Secondary Objective: To evaluate the anti-leukemic activity of CD19-CD22-CAR T cells.
Want to learn more about this trial?
Request More InfoInterventions
FludarabineDRUG
IV
CyclophosphamideDRUG
IV
MesnaDRUG
IV
CD19-CD22 CAR T cell infusionDEVICE
CAR T cell infusion will be given intravenously, either centrally or peripherally.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | United States |